- Home
- INMB vs RVPH Comparison
INMB vs RVPH Comparison
Compare INMB & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INMB
- RVPH
- Stock Information
- Founded
- INMB 2015
- RVPH 2006
- Country
- INMB United States
- RVPH United States
- Employees
- INMB N/A
- RVPH N/A
- Industry
- INMB Biotechnology: Pharmaceutical Preparations
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- INMB Health Care
- RVPH Health Care
- Exchange
- INMB Nasdaq
- RVPH Nasdaq
- Market Cap
- INMB 103.1M
- RVPH 87.6M
- IPO Year
- INMB 2019
- RVPH N/A
- Fundamental
- Price
- INMB $6.53
- RVPH $2.00
- Analyst Decision
- INMB Strong Buy
- RVPH Strong Buy
- Analyst Count
- INMB 2
- RVPH 5
- Target Price
- INMB $21.00
- RVPH $12.00
- AVG Volume (30 Days)
- INMB 369.6K
- RVPH 3.3M
- Earning Date
- INMB 10-31-2024
- RVPH 11-14-2024
- Dividend Yield
- INMB N/A
- RVPH N/A
- EPS Growth
- INMB N/A
- RVPH N/A
- EPS
- INMB N/A
- RVPH N/A
- Revenue
- INMB $42,000.00
- RVPH N/A
- Revenue This Year
- INMB N/A
- RVPH N/A
- Revenue Next Year
- INMB N/A
- RVPH N/A
- P/E Ratio
- INMB N/A
- RVPH N/A
- Revenue Growth
- INMB N/A
- RVPH N/A
- 52 Week Low
- INMB $4.32
- RVPH $0.60
- 52 Week High
- INMB $14.74
- RVPH $4.83
- Technical
- Relative Strength Index (RSI)
- INMB 64.22
- RVPH 56.24
- Support Level
- INMB $6.04
- RVPH $1.56
- Resistance Level
- INMB $6.83
- RVPH $1.86
- Average True Range (ATR)
- INMB 0.56
- RVPH 0.25
- MACD
- INMB 0.17
- RVPH -0.02
- Stochastic Oscillator
- INMB 86.76
- RVPH 72.13
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.